The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
Open accessAbstract
Treatments that target immune checkpoints, such as the one mediated by programmed cell death protein 1 (PD-1) and its ligand PD-L1, have been approved for treating human cancers with durable clinical benefit. However, many patients with cancer fail to respond to compounds that target the PD-1 and PD-L1 interaction, and the underlying mechanism(s) is not well understood. Recent studies revealed that response to PD-1-PD-L1 blockade might correlate with PD-L1 expression levels in tumour cells. Hence, it is important to understand the mechanistic pathways that control PD-L1 protein expression and stability, which can offer a molecular basis to improve the clinical response rate and efficacy of PD-1-PD-L1 blockade in patients with cancer. Here we show that PD-L1 protein abundance is regulated by cyclin D-CDK4 and the cullin 3-SPOP E3 ligase via proteasome-mediated degradation. Inhibition of CDK4 and CDK6 (hereafter CDK4/6) in vivo increases PD-L1 protein levels by impeding cyclin D-CDK4-mediated phosphorylation of speckle-type POZ protein (SPOP) and thereby promoting SPOP degradation by the anaphase-promoting complex activator FZR1. Loss-of-function mutations in SPOP compromise ubiquitination-mediated PD-L1 degradation, leading to increased PD-L1 levels and reduced numbers of tumour-infiltrating lymphocytes in mouse tumours and in primary human prostate cancer specimens. Notably, combining CDK4/6 inhibitor treatment with anti-PD-1 immunotherapy enhances tumour regression and markedly improves overall survival rates in mouse tumour models. Our study uncovers a novel molecular mechanism for regulating PD-L1 protein stability by a cell cycle kinase and reveals the potential for using combination treatment with CDK4/6 inhibitors and PD-1-PD-L1 immune checkpoint blockade to enhance therapeutic efficacy for human cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, several critical proteins including CMTM4, CMTM6, GSK3β, CSN5, CDK4, CDK6, and palmitoylated B3GNT3 have been shown to affect post-translational PD-L1 stability31–36.”
From PRDM1/BLIMP1 induces cancer immune evasion by modulating the USP22-SPI1-PD-L1 axis in hepatocellular carcinoma cells (2022) · cites this paper as [36]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“the Cullin 3-SPOP E3-ligase complex can directly ubiquitinate PD-L1 in a cell-cycle dependent manner, leading to its degradation [15].”
From Characterizing the molecular regulation of inhibitory immune checkpoints with multimodal single-cell screens (2021) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“First, as previously described [15], perturbation of the CUL3-SPOP complex interferes with the ubiquitination of PD-L1, directly enhancing its stability and protein expression level.”
From Characterizing the molecular regulation of inhibitory immune checkpoints with multimodal single-cell screens (2021) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“we verified that perturbation of BHLH transcription factor MYC [12] and the ubiquitin ligase CUL3 [15] both increased PD-L1 protein levels, consistent with previous reports.”
From Characterizing the molecular regulation of inhibitory immune checkpoints with multimodal single-cell screens (2021) · cites this paper as [15]
In the citing paper
“CDK4 was shown to have kinase activity towards SPOP, a cullin 3 E3 ubiquitin ligase adaptor protein that can interact with PD-L1 (Zhang et al., 2018).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Zhang et al., 2018
In the citing paper
“Treatment with palbociclib inhibits SPOP phosphorylation, promoting its degradation and blocking PD-L1 proteasome mediated degradation.”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Zhang et al., 2018
In the citing paper
“Combining palbociclib with a PD-1 blockade enhanced tumor regression and improved overall survival in mouse xenograft models of colon adenocarcinoma (Deng et al., 2017; Zhang et al., 2018).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Zhang et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,261
The Molecular Taxonomy of Primary Prostate Cancer
Abeshouse, A. A., Ahn, J., Akbani, R., Ally, A., Amin, S. B., Andry, C., Annala, M., Aprikian, A. G., Armenia, J., Arora, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.10.025 · Cited by 3,126
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990
Self-citationTaxol stabilizes microtubules in mouse fibroblast cells.
Schiff, P. B., & Horwitz, S. B. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.3.1561 · Cited by 1,971
Cell cycle proteins as promising targets in cancer therapy
Otto, T., & Siciński, P. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,931
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer
Barbieri, C. E., Baca, S. C., Lawrence, M. S., Demichelis, F., Blattner, M., Theurillat, J.-P. P., White, T. A., Stojanov, P., Allen, E. M. V., Stransky, N., et al. (2012) · Nature Genetics · doi:10.1038/ng.2279 · Cited by 1,550
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 1,000
Unlocking New Avenues in Breast Cancer Treatment: The Synergy of Kinase Inhibitors and Immunotherapy
Bravo, M. J., Burgos-Molina, A. M., García‐Aranda, M., Redondo, M., & Téllez, T. (2023) · Cancers · doi:10.3390/cancers15235499 · Cited by 12
Wu, J., Pang, X., Yang, X., Zhang, M., Chen, B.-J., Fan, H., Wang, H., Yu, X., Tang, Y., & Liang, X. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007670 · Cited by 13
Self-citationRole of the ubiquitin–proteasome system on macrophages in the tumor microenvironment
Xiao, Y., Liu, R., Li, N., Li, Y., & Huang, X. (2024) · Journal of Cellular Physiology · doi:10.1002/jcp.31180 · Cited by 12
PKCα inhibitors promote breast cancer immune evasion by maintaining PD-L1 stability
Yu, J.-J., Xiang, Y., Gao, Y.-Z., Chang, S., Kong, R., Lv, X.-X., Yu, J.-M., Jin, Y., Li, C.-X., Ma, Y.-R., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.08.003 · Cited by 12
Macy, M. E., Mody, R. J., Reid, J. M., Piao, J., Saguilig, L., Alonzo, T. A., Berg, S. L., Fox, E., Weigel, B. J., Hawkins, D. S., et al. (2024) · JCO Precision Oncology · doi:10.1200/po-24-00418 · Cited by 15
Zhao, Y., Liu, D., Yang, W., He, W., Yan, J., & Yao, L. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03171-x · Cited by 12
Hao, Q., Zhao, W., Li, Z., Lai, Y., Wang, Y., Yang, Q., & Zhang, L. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117465 · Cited by 12
After a CDK4/6 Inhibitor: State of the Art in Hormone Receptor–Positive Metastatic Breast Cancer
Teysir, J., Lloyd, M. R., Alkassis, S., Callahan, R. D., Fairley, R., Wander, S. A., Bardia, A., & Jhaveri, K. L. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473372 · Cited by 14
Huang, X., Tang, T., Zhang, G., Hong, Z., Xu, J., Yadav, D. K., Bai, X., & Liang, T. (2020) · npj Precision Oncology · doi:10.1038/s41698-020-00136-1 · Cited by 11
Implications of TGFβ Signaling and CDK Inhibition for the Treatment of Breast Cancer
Decker, J. T., Ma, J. A., Shea, L. D., & Jeruss, J. S. (2021) · Cancers · doi:10.3390/cancers13215343 · Cited by 11
Insights into the aberrant CDK4/6 signaling pathway as a therapeutic target in tumorigenesis
Rezaeian, A.-H., Inuzuka, H., & Wei, W. (2022) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2022.11.009 · Cited by 12
Self-citationIdentification of STXBP6-IRF1 positive feedback loop in regulation of PD-L1 in cancer
Liu, Y., Huang, Z., Wei, Y., Zhang, M., Li, X., Yang, S., & Wang, H. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02678-6 · Cited by 12
Self-citationYang, W.-C., Wei, M., Shen, Y., Huang, C., & Kuo, S. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-025-01173-3 · Cited by 11
AURKA inhibitor-induced PD-L1 upregulation impairs antitumor immune responses
Meng, B., Zhao, X., Jiang, S., Xu, Z., Li, S., Wang, X., Ma, W., Li, L., Liu, D., Zheng, J., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1182601 · Cited by 12
Prolyl isomerase Pin1 sculpts the immune microenvironment of colorectal cancer
Li, Y., Yuan, Z., Wang, L., Yang, J. H., Pu, P., Le, Y., Chen, X., Wang, C., Gao, Y., Liu, Y., et al. (2024) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111041 · Cited by 11
Self-citationGABA/baclofen stabilizes PD-L1 and enhances immunotherapy of breast cancer
Sun, X., Lin, M., Tian, Z., Ma, Y., & Lv, L. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28600 · Cited by 11
Advances in the mechanism of CDK4/6 inhibitor resistance in HR+/HER2− breast cancer
Wu, S., Xu, J., Ma, Y., Liang, G., Wang, J., & Sun, T. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241282499 · Cited by 15
Liu, Y., Deng, Y., Yang, C., & Naranmandura, H. (2024) · Bioengineering · doi:10.3390/bioengineering11111084 · Cited by 13
Chen, S., Lin, J., Yang, Z., Wang, Y., Wang, Q., Wang, D., Qu, Y., Lin, Q., Liu, J., Shi, Y., et al. (2025) · Cell Death and Differentiation · doi:10.1038/s41418-025-01582-9 · Cited by 13
Self-citationRoles of KDM5 demethylases in therapeutic resistance of cancers
Chen, X., Chen, M., Gu, X., Zhou, Q., Zhao, Y., Yang, Y., Zhang, H., & Yang, X. (2025) · Epigenetics & Chromatin · doi:10.1186/s13072-025-00624-3 · Cited by 11
Gong, H., Liu, F., Liu, X., Min, S., Wu, N., Liu, Y., Liu, Y., Zhang, Y., Zhang, Y., Zhang, Y., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.05.028 · Cited by 11
Palicelli, A., Bonacini, M., Croci, S., Bisagni, A., Zanetti, E., de Biase, D., Sanguedolce, F., Ragazzi, M., Zanelli, M., Chaux, A., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11121312 · Cited by 11
NEDD4L suppresses PD-L1 expression and enhances anti-tumor immune response in A549 cells
Zhong, B., Zheng, J., Wen, H., Liao, X., Chen, X., Rao, Y., & Yuan, P. (2022) · Genes & Genomics · doi:10.1007/s13258-022-01238-9 · Cited by 11
Song, N., Deng, L., Zeng, L., Li, H., Liu, C., Liu, L., & Fu, R. (2023) · Molecular Carcinogenesis · doi:10.1002/mc.23591 · Cited by 11
Maltol has anti-cancer effects via modulating PD-L1 signaling pathway in B16F10 cells
Han, N., Park, H., Ko, S., & Moon, P. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1255586 · Cited by 11
Kan, A., Liu, S., He, M., Wen, D., Deng, H., Huang, L., Lai, Z., Huang, Y., & Shi, M. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100939 · Cited by 11
Self-citationEnhancing immunogenic responses through CDK4/6 and HIF2α inhibition in Merkel cell carcinoma
Lee, J. H., Lee, J. D., Paulson, K. G., Voillet, V., Berndt, A., Church, C. D., Lachance, K., Park, S. Y., Yamamoto, N., Cromwell, E. A., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e23521 · Cited by 11
Novel insights into the pathogenesis and treatment of NRAS mutant melanoma
Zhao, J. W., Galvez, C., Beckermann, K. E., Johnson, D. B., & Sosman, J. A. (2021) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2021.1938545 · Cited by 11
Targeting oncogenic signal pathway to improve cancer immunotherapy: Insights and perspectives
Yang, Q., Sun, H., & Sun, Z. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117043 · Cited by 11
SPOP Is a Key Trigger of Pathological Cardiac Hypertrophy and Heart Failure
Wu, H., Zhuang, Y., Yue, Y., Liu, J., Han, J., Yao, Y., Xu, X., Liu, J., Li, Y., Yang, Z., et al. (2025) · Circulation Research · doi:10.1161/circresaha.125.326129 · Cited by 10
E3 Ubiquitin Ligases: Structures, Biological Functions, Diseases, and Therapy
Wang, H., Peng, J., Li, H., Lan, Y., Guo, J., Qiu, Q., & Huang, X. (2025) · MedComm · doi:10.1002/mco2.70528 · Cited by 13
Self-citationElsayed, I., Elsayed, N., Feng, Q., Sheahan, K. D., Moran, B., & Wang, X. (2022) · Cancer Biomarkers · doi:10.3233/cbm-210222 · Cited by 10
Arndt, C., Tunger, A., Wehner, R., Rothe, R., Kourtellari, E., Luttosch, S., Hannemann, K., Koristka, S., Loureiro, L. R., Feldmann, A., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.970457 · Cited by 11
CK2-dependent degradation of CBX3 dictates replication fork stalling and PARP inhibitor sensitivity
Ma, J., Ren, D., Wang, Z., Li, W., Li, L., Liu, T., Ye, Q., Lei, Y., Jian, Y., Ma, B., et al. (2024) · Science Advances · doi:10.1126/sciadv.adk8908 · Cited by 10
Cancer therapy by cyclin-dependent kinase inhibitors (CDKIs): bench to bedside
Hassanzadeh, A., Shomali, N., Kamrani, A., Soltani‐Zangbar, M. S., Nasiri, H., & Akbari, M. (2024) · EXCLI journal · doi:10.17179/excli2024-7076 · Cited by 11
The Tumor Suppressor TPD52‐Governed Endoplasmic Reticulum Stress is Modulated by APC Cdc20
Dan, W., Fan, Y., Wang, Y., Hou, T., Wei, Y., Liu, B., Li, M., Chen, J., Fang, Q., Que, T., et al. (2024) · Advanced Science · doi:10.1002/advs.202405441 · Cited by 10
Zheng, M., Li, J., Guo, H., Zhang, J., Wang, L., Jiang, K.-F., Wu, H., He, Q., Ding, L., & Yang, B. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01411-8 · Cited by 11
Self-citationShu, C., Li, J., Rui, J., Fan, D., Niu, Q., Bai, R., Cicka, D., Doyle, S. P., Wahafu, A., Zheng, X., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57297-5 · Cited by 11
Deciphering molecular pathways in urological cancers: A gateway to precision therapeutics
Hushmandi, K., Farahani, N., Einollahi, B., Salimimoghadam, S., Alimohammadi, M., Liang, L., Liu, L., & Sethi, G. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.06.009 · Cited by 11
Sun, R., Peng, J. C., Wang, Z., Yan, B., Zhu, S., Huang, Z., Zhang, J., Ding, D., Li, X., Wang, L., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2413732122 · Cited by 11
Self-citationTargeting the cell-cycle machinery for cancer therapy
Peng, Y., Liu, J., Inuzuka, H., Liu, J., & Wei, W. (2025) · Trends in Cell Biology · doi:10.1016/j.tcb.2025.08.008 · Cited by 12
Self-citationHe, L., Peng, Y., Leong, L., Zhou, J., Tang, D., Wang, W., Wu, X., Lei, J. H., Ye, Y., Feng, Y., et al. (2025) · Advanced Science · doi:10.1002/advs.202511330 · Cited by 12
Targeting protein tyrosine phosphatases for CDK6-induced immunotherapy resistance
Gao, X., Wu, Y., Chick, J. M., Abbott, A., Jiang, B., Wang, J., Comte‐Walters, S., Johnson, R. H., Oberholtzer, N. P., Nishimura, M. I., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112314 · Cited by 11
Self-citationRuan, Y., Xie, L., & Zou, A. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04974-x · Cited by 10
Zhu, J.-P., Ma, Y.-R., Teng, Y., Chen, J., Banwell, M. G., & Lan, P. (2020) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.0c02890 · Cited by 10
Identification of chemical compounds regulating PD‐L1 by introducing HiBiT‐tagged cells
Uchida, Y., Matsushima, T., Kurimoto, R., Chiba, T., Inutani, Y., & Asahara, H. (2021) · FEBS Letters · doi:10.1002/1873-3468.14032 · Cited by 9
Tamura, R., Yoshihara, K., Matsuo, K., Yachida, N., Miyoshi, A., Takahashi, K., Sugino, K., Yamaguchi, M., Mori, Y., Suda, K., et al. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.08.009 · Cited by 10
Enhancing Adoptive Cell Transfer with Combination BRAF-MEK and CDK4/6 Inhibitors in Melanoma
Lau, P. K. H., Cullinane, C. M., Jackson, S., Walker, R., Smith, L. K., Slater, A. A., Kirby, L., Patel, R. P., von Scheidt, B., Slaney, C. Y., et al. (2021) · Cancers · doi:10.3390/cancers13246342 · Cited by 10
Associating Immunotherapy and Targeted Therapies: Facts and Hopes
Ladoire, S., Rébé, C., & Ghiringhelli, F. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1184 · Cited by 10
Zou, W., Luo, X., Gao, M., Chang, Y., Wan, X., Yu, S., Wu, Y., Wang, A., Fenical, W., Wei, Z., et al. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16054 · Cited by 12
Checkpoints Under Traffic Control: From and to Organelles
Deng, S., Zhou, X., & Xu, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_18 · Cited by 10
Suppression of AGRN enhances CD8 + T cell recruitment and inhibits breast cancer progression
Tao, J., Li, S., Zhuang, M., Zhai, C., Zeng, H., Mao, Y., & Liu, X. (2024) · The FASEB Journal · doi:10.1096/fj.202302288r · Cited by 9
ESCO2’s oncogenic role in human tumors: a pan-cancer analysis and experimental validation
Huang, Y., Chen, D., Bai, Y., Zhang, Y., Zheng, Z., Fu, Q., Yi, B., Jiang, Y., Zhang, Z., & Zhu, J. (2024) · BMC Cancer · doi:10.1186/s12885-024-12213-w · Cited by 10
Self-citationPrediction of immunotherapy response using mutations to cancer protein assemblies
Kong, J., Zhao, X., Singhal, A., Park, S., Bachelder, R. E., Shen, J., Zhang, H., Moon, J., Ahn, C.-H., Ock, C., et al. (2024) · Science Advances · doi:10.1126/sciadv.ado9746 · Cited by 9
Liu, J., Deng, Y., Pu, Z., Miao, Y., Hao, Z., Wang, H., Zhang, S., Liu, H., Wang, J., Lv, Y., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.173700 · Cited by 10
Self-citation“Dissecting the role of T cell exhaustion in cancer progression: a multifaceted approach“
Li, X., & Song, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1646292 · Cited by 12
Preclinical Head and Neck Squamous Cell Carcinoma Models for Combined Targeted Therapy Approaches
Schoenwaelder, N., Krause, M., Freitag, T., Schneider, B., Zonnur, S., Zimpfer, A., Becker, A., Salewski, I., Strüder, D., Lemcke, H., et al. (2022) · Cancers · doi:10.3390/cancers14102484 · Cited by 9
Yan, W., Shi, X., Wang, H., Liao, A., & Yang, W. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03476-7 · Cited by 9
Self-citationTian, Y., Zhou, J., Qiao, J., Liu, Z., Gu, L., Zhang, B., Lu, Y., Xing, R., & Deng, D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1038380 · Cited by 9
The role of ubiquitin pathway‐mediated regulation of immune checkpoints in cancer immunotherapy
Zhou, X., Fu, C., & Chen, X. (2023) · Cancer · doi:10.1002/cncr.34729 · Cited by 10
CDK4/6i enhances the antitumor effect of PD1 antibody by promoting TLS formation in ovarian cancer
Feng, W., Jiang, D., Xu, Y., Li, Y., Chen, L., Zhao, M., Shen, Y., Liao, W., Yang, H., & Li, J. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e19760 · Cited by 9
Targeting the PD-L1 cytoplasmic domain and its regulatory pathways to enhance cancer immunotherapy
Chai, F., Li, P., Liu, X., Zhou, Z., & Ren, H. (2023) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjad070 · Cited by 9
Jiang, A., Liu, Y., Zhu, B., Fang, Y., Qu, L., Yang, Q., Luo, P., Cai, C., & Wang, L. (2024) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2024.01.005 · Cited by 9
E3 Ubiquitin Ligases in Cancer and Their Pharmacological Targeting
Ong, J. Y., & Torres, J. Z. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.82883 · Cited by 8
[Research Progress of CDK4/6 Inhibitors in Non-small Cell Lung Cancer].
Qin, Q., Ren, Y., & Zhong, D. (2020) · PubMed Central · doi:10.3779/j.issn.1009-3419.2020.03.07 · Cited by 9
Zhou, P., Lu, Y., Xun, Y., Xu, J., Liu, C., Xia, Q., Lu, J., Wang, S., & Hu, J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.659294 · Cited by 9
Huang, D., Montigny, C., Zheng, Y., Beswick, V., Li, Y., Cao, X., Barbot, T., Jaxel, C., Liang, J., Xue, M., et al. (2019) · Angewandte Chemie · doi:10.1002/ange.201914836 · Cited by 9
Li, W., Lu, Z., Pan, D., Zhang, Z., He, H., Wu, J., & Peng, N. (2022) · Journal of Oncology · doi:10.1155/2022/5504173 · Cited by 9
Abbosh, C., Swanton, C., & Birkbak, N. J. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy017 · Cited by 8
Xu, X., Qian, Y., Tian, M., Ding, C., Guo, H., Tang, J. P., Pi, G., Wu, Y., Dai, Z., & Jin, X. (2023) · Nutrition and Cancer · doi:10.1080/01635581.2023.2203355 · Cited by 8
Chen, Z., Yao, M., Ao, X., Gong, Q., Yang, Y., Liu, J., Lian, Q., Xu, X. M., & Zuo, L. (2023) · Chinese Journal of Traumatology · doi:10.1016/j.cjtee.2023.11.003 · Cited by 12
Cai, M., Xu, M., Yu, D., Wang, Q., & Liu, S. (2024) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2024085 · Cited by 8
A comprehensive review of mechanisms underlying resistance to immune checkpoint inhibitors
Bertucci, A., -, D. T. K., Billon, E., Fernez, T., & Rochigneux, P. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1735741 · Cited by 11
The Landscape of Immunotherapy for Retroperitoneal Sarcoma
Gingrich, A. A., Nassif, E. F., Roland, C. L., & Keung, E. Z.-Y. (2023) · Current Oncology · doi:10.3390/curroncol30020165 · Cited by 8
Zheng, Y., Zhang, Z., Li, D., Huang, R. R., & Ning, S. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189174 · Cited by 8
Murphy, J. M., Jeong, K., Ahn, E.-Y. E., & Lim, S. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102013 · Cited by 8
Guo, X., Chen, H., Zhou, Y., Shen, L., Wu, S., & Chen, Y. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2097067 · Cited by 7
Zhang, T., Zhang, C., Fu, Z., & Gao, Q. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091768 · Cited by 8
Targeting EZH2 Increases Therapeutic Efficacy of Check-Point Blockade in Models of Prostate CancerPreprint
Sheahan, A. V., Morel, K. L., Burkhart, D. L., Baca, S. C., Labbé, D. P., Roehle, K., Heckler, M., Calagua, C., Ye, H., Galbo, P. M., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/730135 · Cited by 8
Fraire, C. R., Desai, K. K., Jagadeeswaran, I., Obalapuram, U. A., Mendyka, L. K., Rajaram, V., Sebastian, T., Wang, Y., Onel, K., Lee, J., et al. (2025) · Genes & Development · doi:10.1101/gad.352485.124 · Cited by 8
ROS, Redox Regulation, and Anticancer Therapy
Bansal, M. P. (2023) · Springer eBooks · doi:10.1007/978-981-99-7342-2_9 · Cited by 7
Ilieva, N., Pencheva, M. M., Hadzhiev, H., Tashkova, D., Daskalova, E., Georgiev, P., & Genova, S. (2024) · Diagnostics · doi:10.3390/diagnostics14232672 · Cited by 7
Roles of CDK12 mutations in PCa development and treatment
Jiang, C., Hong, Z., Liu, S., Hong, Z., & Dai, B. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189247 · Cited by 8
Zhang, Y., Yin, K., Ma, R., Sun, Y., Wang, L., & Yin, D. (2025) · iScience · doi:10.1016/j.isci.2025.112615 · Cited by 7
Self-citationLMNB2-mediated high PD-L1 transcription triggers the immune escape of hepatocellular carcinoma
Li, Y., Zhu, J., Zhai, F., Ge, Y., Zhan, Z., Wang, S., Kong, L., Zhao, J., Hu, L., Wang, S., et al. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02540-7 · Cited by 7
Self-citationTargeting USP47 enhances immunotherapy in hepatocellular carcinoma by destabilizing PD-L1
Jiang, Y., Yu, Z., Wang, J., Wu, Y., Li, Z., Le, T., Yang, C., Wei, Y., Zhang, G., & Ma, H. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115024 · Cited by 7
Tzetzo, S. L., Schultz, E., Wang, J., Rosenheck, H. R., Mahan, S., Knudsen, E. S., & Witkiewicz, A. K. (2025) · npj Breast Cancer · doi:10.1038/s41523-025-00767-2 · Cited by 7
Targeted destruction of VISTA boosts anti-tumor immunotherapy
Chen, L., Bu, X., Sun, Y., Huang, D., Chen, Y., Hou, T., Hu, X., Wang, J., Yan, P., Qi, Y., et al. (2025) · Cell Research · doi:10.1038/s41422-025-01194-5 · Cited by 7
Self-citationScordamaglia, D., Talia, M., Zicarelli, A., Mondino, A. A., Rosis, S. D., Dio, M. D., Silvestri, F., Meliti, C., Cirillo, F., Francesco, E. M. D., et al. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10307-w · Cited by 9
Adkins, D. R., Ley, J. C., Cohen, J. A., & Oppelt, P. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000617 · Cited by 8
Dynamic control of reflection from a metasurface with distinct modulating mechanisms
Liu, S., Pang, Y., Qu, B., Li, Y., Wang, J., & Xu, Z. (2024) · Smart Materials and Structures · doi:10.1088/1361-665x/ad223a · Cited by 7
Hippo signaling modulation and its biological implications in urological malignancies
Tong, T., Huang, M., Yan, B., Lin, B., Yu, J., Teng, Q., Li, P., & Pang, J. (2024) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2024.101280 · Cited by 7
Cholesterol suppresses AMFR-mediated PDL1 ubiquitination and degradation in HCC
Shao, W., Li, Y., Xu, Z., Zhang, S., Fan, M.-H., Zhang, D., Chen, Z., Yi, C., Wang, S.-H., Zhu, W., et al. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-05106-w · Cited by 7
Depleting Tumor Cells Expressing Immune Checkpoint Ligands—A New Approach to Combat Cancer
Marcucci, F., & Rumio, C. (2021) · Cells · doi:10.3390/cells10040872 · Cited by 8
Neddylation and anti-tumor immunity
Wang, X., Best, S., & Danilov, A. V. (2021) · Oncotarget · doi:10.18632/oncotarget.28019 · Cited by 7
An Extended PD-L2 Cytoplasmic Domain Results From Alternative Splicing in NSCLC Cells
Dietz, L. L., Furman, N. T., Larsen, T. V., Daugaard, T. F., Thomsen, E. A., Lade‐Keller, J., Aagaard, L., Sørensen, B. S., & Nielsen, A. L. (2022) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000439 · Cited by 7
Deciphering the tumour immune microenvironment of hepatocellular carcinoma
Liu, S., Jia, M., & Dai, R. (2023) · Scandinavian Journal of Immunology · doi:10.1111/sji.13327 · Cited by 7
Roozitalab, G., Abedi, B., İmani, S., Farghadani, R., & Kaboli, P. J. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10174-x · Cited by 7
Mao, Y., Wu, C., Wang, X., Zhang, F., Qi, X., Li, X., Li, P., & Tang, B. (2024) · Communications Biology · doi:10.1038/s42003-024-06245-y · Cited by 7
Luo, D., Kuang, F. L., Du, J., Zhou, M., Peng, F., Gan, Y., Fang, C., Yang, X., Li, B., & Su, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.677609 · Cited by 7
Metadata
- Authors
- Zhang, J., Bu, X., Wang, H., Zhu, Y., Geng, Y., Nihira, N. T., Tan, Y., Ci, Y., Wu, F., Dai, X., Guo, J., Huang, Y.-H., Fan, C., Ren, S., Sun, Y., Freeman, G. J., Sicinski, P., & Wei, W.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
- Second Military Medical University (CN)
- Corresponding author
- Freeman, Gordon J.
- Wei, Wenyi
- ORCID
- Venue
- Nature
- Published
- 2017-11-16
- Volume
- 553
- Issue
- 7686
- Pages
- 91-95
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5754234
- OpenAlex
- W2769376007
- Cited by
- 1,013
- References
- 43
- Citations by year
- 2026: 81 · 2025: 123 · 2024: 138 · 2023: 140 · 2022: 134 · 2021: 157 · 2020: 118 · 2019: 78 · 2018: 43
- FWCI
- 28.82
- Type
- journal article
- Language
- en
- Update notices
- correction (2019-07-03)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (R01CA190509, R01CA229307, R01CA200573, K99CA212292, R01CA177910, P50CA101942, R01CA132740, R01CA202634, P01CA080111, R01CA200651, R01CA083688)
- National Institute of General Medical Sciences (R01GM094777, R01GM089763)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- PD-L1, anti-PD-1 therapy, CDK4/6 inhibitors, FZR1, proteasomal degradation, polyubiquitination, tumor immune evasion, immune checkpoint blockade, combination immunotherapy, tumor immune microenvironment
- MeSH terms
- Animals, Cell Cycle, Cell Line, Female, Humans, Immunologic Surveillance, Male, Neoplasms, Nuclear Proteins, Phosphorylation, Prostatic Neoplasms, Repressor Proteins, Lymphocytes, Tumor-Infiltrating, Tumor Escape, Cullin Proteins, Proteasome Endopeptidase Complex, 14-3-3 Proteins, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Mice, Protein Stability, Cyclin D, Proteolysis, B7-H1 Antigen, Programmed Cell Death 1 Receptor, Cdh1 Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
